AMENDMENT TO THE CLAIMS

1. (**Original**) A method of treating or preventing chronic renal failure in a mammal, comprising conjointly administering to said mammal an OP/BMP morphogen and an Angiotensin-Converting Enzyme Inhibitor (ACEI).

2. (**Original**) A method of treating or preventing chronic renal failure in a mammal, comprising conjointly administering to said mammal an OP/BMP morphogen and an Angiotensin II Receptor Antagonist (AIIRA).

3. (**Original**) A method of treating or preventing chronic renal failure in a mammal, comprising conjointly administering to said mammal an inducer of endogenous OP/BMP morphogen expression and an Angiotensin-Converting Enzyme Inhibitor (ACEI).

4. (**Original**) A method of treating or preventing chronic renal failure in a mammal, comprising conjointly administering to said mammal an inducer of endogenous OP/BMP morphogen expression and an Angiotensin II Receptor Antagonist (AIIRA).

5. (**Original**) A method of treating or preventing chronic renal failure in a mammal, comprising conjointly administering to said mammal an agonist of an OP/BMP morphogen receptor and an Angiotensin-Converting Enzyme Inhibitor (ACEI).

6. (**Original**) A method of treating or preventing chronic renal failure in a mammal, comprising conjointly administering to said mammal an agonist of an OP/BMP morphogen receptor and an Angiotensin II Receptor Antagonist (AIIRA).

7-11. (**Canceled**).

12. (**Original**) A method for delaying the need for, or reducing the frequency of, chronic dialysis treatments, comprising conjointly administering to a mammal an OP/BMP morphogen and an ACEI.

13. (**Original**) A method for delaying the need for, or reducing the frequency of, chronic dialysis treatments, comprising conjointly administering to a mammal an OP/BMP morphogen and an AIIRA.

14. (**Original**) A method for delaying the need for, or reducing the frequency of, chronic dialysis treatments, comprising conjointly administering to said mammal an inducer of endogenous OP/BMP morphogen expression and an ACEI.

15. (**Original**) A method for delaying the need for, or reducing the frequency of, chronic dialysis treatments, comprising conjointly administering to said mammal an inducer of endogenous OP/BMP morphogen expression and an AIIRA.

16. (**Original**) A method for delaying the need for, or reducing the frequency of, chronic dialysis treatments, comprising conjointly administering to said mammal an agonist of an OP/BMP morphogen receptor and an ACEI.

17. (**Original**) A method for delaying the need for, or reducing the frequency of, chronic dialysis treatments, comprising conjointly administering to said mammal an agonist of an OP/BMP morphogen receptor and an AIIRA.

18-55. (**Canceled**).

56. (**Original**) A pharmaceutical composition comprising a therapeutically effective amount an ACE inhibitor and an OP/BMP morphogen formulated with pharmaceutically acceptable salt, carrier, excipient or diluent.

57. (**Original**) A pharmaceutical composition comprising a therapeutically effective amount an AIIRA and an OP/BMP morphogen formulated with pharmaceutically acceptable salt, carrier, excipient or diluent.

58-68. (**Canceled**)

69. (**New**) The pharmaceutical composition of claim 56, wherein the ACE inhibitor is Enalapril.

70. (New) The pharmaceutical composition of claim 56, wherein the morphogen is the polypeptide of SEQ ID NO: 3.

71. (New) The pharmaceutical composition of claim 56, wherein the morphogen is a first polypeptide including at least a C-terminal cysteine domain of a protein selected from: a pro form, a mature form, or a soluble form of a second polypeptide, wherein said second polypeptide is: OP-1, OP-2, OP-3, BMP2, BMP3, BMP4, BMP5, BMP6, or BMP9.

72. (New) The pharmaceutical composition of claim 56, wherein said morphogen comprises a polypeptide having at least 70% homology or 50% identity with an amino acid sequence of a C-terminal seven-cysteine domain of human OP-1 (SEQ ID NO: 2).

73. (New) The pharmaceutical composition of claim 72, wherein said polypeptide has at least 75% homology or 60% identity with an amino acid sequence of a C-terminal seven-cysteine domain of human OP-1 (SEQ ID NO: 2).

74. (New) The pharmaceutical composition of claim 72, wherein said polypeptide has at least 80% homology or 70% identity with an amino acid sequence of a C-terminal seven-cysteine domain of human OP-1 (SEQ ID NO: 2).

75. (New) The pharmaceutical composition of claim 72, wherein said polypeptide has at least 90% identity with an amino acid sequence of a C-terminal seven-cysteine domain of human OP-1 (SEQ ID NO: 2).

76. (New) The pharmaceutical composition of claim 56, wherein said ACEI is: any one compound of the formulas I-XXVIII or their salts thereof; acylmercapto and mercaptoalkanoyl prolines; captopril (1-[(2S)-3-mercapto-2-methylpropionyl]-L-proline); ether or thioether mercaptoacyl prolines; zofenopril; carboxyalkyl dipeptides; enalapril (N-(1-ethoxycarbonyl-3-phenylpropyl)-L-ananyl-L-proline); lisinopril; quinapril; ramipril; carboxyalkyl dipeptide mimics; cilazapril; benazapril; phosphinylalkanoyl prolines; fosinopril; trandolopril; phosphonamidate substituted amino or imino acids; phosphonate substituted amino or imino acids and salts thereof; ceronapril ((S)-1-[6-amino-2-[[hydroxyl(4-phenylbutyl)phosphinyl]oxy]-1-oxohexyl]-L-proline); BRL 36,378; MC-838; CGS 14824 (3-([1-ethoxycarbonyl-3-phenyl-(1S)-

propyl]-amino)-2,3,4,5-tetrahydro-2-oxo-1-(3S)-benzazepine-1 acetic acid HCL); CGS 16,617 (3(S)-[[(1S)-5-amino-1-carboxypentyl]amino]2,3,4,5-tetrahydro-2-oxo-1H-1-benzazepine-1-ethanoic acid); Cetapril (alacepril, Dainippon); Ru 44570; Cilazapril; Ro 31-2201; Lisinopril; Indalapril (delapril); Rentiapril (fentiapril, Santen); Indolapril; Spirapril; Perindopril; Quinapril; CI 925 ([3S-[2[R(*)R(*)]]3R(*)]-2-[2-[[1-(ethoxy-carbonyl)-3-phenylpropyl]amino[-1-oxopropyl]-1,2,3,4-tetrahydro-6,7-dimethoxy-3-isoquinolinecarboxylic acid HCL); WY-44221; mercapto-containing compounds; pivopril; YS980; Omapatrilat; Alacepril; moveltopril; quinaprilat; moexipril; perinodpril (S-9490); pentopril; ancovenin; phenacein; or nicotianamin.

77. (New) The pharmaceutical composition of claim 57, wherein said AIIRA is: Losartan (Cozaar®), Valsartan (Diovan®), Irbesartan (Avapro®), Candesartan (Atacand®), Telmisartan (Micardis®), tasosartan, zolarsartan, Teveten (eprosartan mesylate) or olmesartan medoxomil (Benicar).

78. (New) A package pharmaceutical comprising the pharmaceutical composition of claim 56, in association with instructions for administering the composition to a mammal for treatment or prevention of chronic renal failure.